ACRS Q2 2019 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$407M

Q2 2019 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$6M+59.5% YoY

Gross Profit

$3M53.9% margin

Operating Income

-$50M-849.0% margin

Net Income

-$50M-850.4% margin

EPS (Diluted)

$-1.21

QoQ Revenue Growth

+16.3%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$217M

Total Liabilities

$80M

Stockholders' Equity

$137M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+59.5%
Gross Profit	$3M	$2M	+26.7%
Operating Income	-$50M	-$32M	-55.7%
Net Income	-$50M	-$31M	-59.8%

Revenue Segments

Product

$5M50%

Rhofade Product

$5M47%

Eskata Product

$272,0003%